Fraunhofer USA Center for Molecular Biotechnology Announces Positive Phase 1 Interim Results for Its Plant-Produced H1N1 Influenza Vaccine

Published: Jun 02, 2011

Fraunhofer USA Center for Molecular Biotechnology (CMB), a not-for-profit, Delaware-based organization focused on developing a proprietary plant-based protein production platform and its applications in vaccine and therapeutic fields, today announced positive interim results from the first human trial of plant-produced H1N1 influenza vaccine (HAC1) that began on September 13, 2010. This Phase 1, single-blind, placebo-controlled, dose-escalation study was conducted to assess the safety and reactogenicity and immunogenicity of CMB’s HAC1. The trial was supported by funding from the Defense Advanced Research Projects Agency (DARPA) and was conducted at the Walter Reed Army Institute of Research Clinical Trials Center (WRAIR-CTC). Safety and reactogenicity assessments were completed at WRAIR-CTC, and immunogenicity evaluation was performed by the Influenza Division of the Centers for Disease Control and Prevention.

Back to news